8VC Names Francisco Gimenez as Partner

venture capital

8VC, a San Francisco, CA-based venture capital firm, named Dr. Francisco Gimenez as partner.

Gimenez originally joined predecessor firm Formation 8 in 2014 as the Data-Scientist-in-Residence and has been a key member of the team since 2016 when 8VC launched. Alongside his work with data and smart enterprise platforms, he has helped develop and execute the firm’s focus on the convergence of biology and technology. Gimenez and colleagues have helped 8VC partner with companies defining technology powered innovation in the biosciences including Synthego, Mantra Biosciences, Sirona Medical, Unlearn.ai, Cambium Biomaterials, BigHat Biosciences, Senti Biosciences, and SyntheX.

Gimenez previously was the Data-Scientist-in-Residence at Formation 8 where he worked with portfolio companies to strategize, prototype, and recruit for data products. He was the founder of Catenus Science, a data science consulting and recruiting firm that used an apprenticeship model to help early stage companies build data science teams.

Gimenez received his Ph.D. from Stanford in Biomedical Informatics, where he was a Ruth L. Kirchstein Fellow. His research focused on clinical decision support for radiology which won him the Martin Epstein award for best paper at the American Medical Informatics Association in 2014. He was the commencement speaker for the Stanford School of Medicine in 2015.

Prior to that, he received his B.S. in Electrical Engineering and Computer Sciences from UC Berkeley while doing research in Parkinson’s disease at UCSF.

Founded by entrepreneur and Palantir co-founder Joe Lonsdale with $3.5 billion in assets under management, 8VC is a technology investment firm backing industry-transforming companies in smart enterprise platforms across industries including financial services, healthcare, logistics and others, and Bio-IT. The predecessor firm Formation 8 was founded in 2012 and today, manages $1.1 billion in committed capital. 8VC was founded in 2016 and manages $2.4 billion in committed capital.



Join the discussion